Education
About Us
Working with TipRanks
Follow Us
ELEVAI Labs Inc. (ELAB)
:ELAB
ELAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.81 - $546.00
Previous CloseN/A
Volume180.10K
Average Volume (3M)135.15K
Market Cap
$2.57M
Enterprise Value-$3.40M
Total Cash (Recent Filing)$3.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding1,375,385
10 Day Avg. Volume55,083
30 Day Avg. Volume135,149
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.25
Enterprise Value/Ebitda1.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ELEVAI Labs Inc. News
ELAB FAQ
What was ELEVAI Labs Inc.’s price range in the past 12 months?
ELEVAI Labs Inc. lowest stock price was $1.81 and its highest was $546.00 in the past 12 months.
What is ELEVAI Labs Inc.’s market cap?
ELEVAI Labs Inc.’s market cap is $2.57M.
When is ELEVAI Labs Inc.’s upcoming earnings report date?
ELEVAI Labs Inc.’s upcoming earnings report date is Aug 13, 2025 which is in 5 days.
How were ELEVAI Labs Inc.’s earnings last quarter?
Currently, no data Available
Is ELEVAI Labs Inc. overvalued?
According to Wall Street analysts ELEVAI Labs Inc.’s price is currently Overvalued.
Does ELEVAI Labs Inc. pay dividends?
ELEVAI Labs Inc. does not currently pay dividends.
What is ELEVAI Labs Inc.’s EPS estimate?
ELEVAI Labs Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ELEVAI Labs Inc. have?
ELEVAI Labs Inc. has 1,375,385 shares outstanding.
What happened to ELEVAI Labs Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ELEVAI Labs Inc.?
Currently, no hedge funds are holding shares in ELAB
Company Description
ELEVAI Labs Inc.
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
ELEVAI Labs Inc. (ELAB) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Ownership Overview
25.70% Insiders
0.82% Other Institutional Investors
74.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---